Acura Pharmaceuticals, Inc. · OTC:ACUR

Acura Pharmaceuticals — Stifel Nicolaus Conference 2012

20 slides from Acura Pharmaceuticals's conference presentation, Sep 4, 2012

  1. Slide 1: Stifel Nicolaus Conference

    Slide 1: Stifel Nicolaus Conference

    September 5, 2012 Stifel Nicolaus Conference Boston, MA Copyright © 2012 Acura Pharmaceuticals. All rights reserved.

  2. Slide 2: Caution Regarding Forward Looking Statements

    Slide 2: Caution Regarding Forward Looking Statements

    Caution Regarding Forward Looking Statements Certain statements in this presentation constitute "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements involve known and unknown risks, uncertainties and other facto

  3. Slide 3: Business Highlights

    Slide 3: Business Highlights

    Business Highlights • FDA approved technology • 1 st Aversion® opioid product launched by Pfizer Feb. 2012 • 1 Aversion® opioid in active development • 6 Aversion® opioids formulations developed • Aversion® (Tamper Resistant) Technology • Impede™ (Meth Resistant) Technology • Targeting Nexafed ® com

  4. Slide 4: Product Portfolio Summary

    Slide 4: Product Portfolio Summary

    Product Portfolio Summary • Broad pipeline of product candidates • Two proprietary technologies: Aversion® and Impede™ Product Area Technology Licensee Status Oxycodone HCL, USP CII Opioid Aversion Pfizer Marketed in the U.S. Hydrocodone/APAP Opioid Aversion * In Development 6 Additional Opioids Opi

  5. Slide 5: Impede Technology

    Slide 5: Impede Technology

    Impede™ Technology Unique mixture of inactive ingredients added to pseudoephedrine HCl tablets designed to disrupt conversion into methamphetamine 5

  6. Slide 6: Pseudoephedrine HCl Tablets with Impede Technology

    Slide 6: Pseudoephedrine HCl Tablets with Impede Technology

    6 (Pseudoephedrine HCl ) 30 mg Tablets • Pseudoephedrine HCl 30 mg Tablets • With Impede™ Technology • Efficacy Demonstrated • Pilot formulation bioequivalent to existing tablets • Meth Resistance Testing • no extraction of pseudoephedrine for further processing in two common Meth extraction methods

  7. Slide 7: Nexafed Development Status

    Slide 7: Nexafed Development Status

    7 Nexafed ® Development Status • Commercial scale - up to 700,000 tablet batches complete • Formulation adjustments do not impact meth resistance profile • Commencing Commercial Process Validation • If successful, expected to be the first commercial product • Bioequivalence testing on validated prod

  8. Slide 8: Nexafed Marketing Status

    Slide 8: Nexafed Marketing Status

    • Expect Nexafed® price to be comparable to existing branded products • Initial distribution expected to be to drug wholesalers • Nationwide coverage targeted • Independent pharmacies in high meth impact areas are anticipated to be early adopters • Chain pharmacists may purchase from drug wholesaler

  9. Slide 9: Nexafed Target Market

    Slide 9: Nexafed Target Market

    9 • $1 billion U.S. non - prescription nasal decongestant market in 2009 1 • Market fragmented by combination and extended - release products incorporating pseudoephedrine HCl and other decongestants • 53% of sales are from phenylephrine containing products • Sold by chain and independent pharmacies

  10. Slide 10: Aversion Technology

    Slide 10: Aversion Technology

    Aversion ® Technology Proprietary mixture of inactive ingredients added to immediate release tablets intended to discourage tampering associated with misuse and abuse 10

  11. Slide 11: Aversion Opioid Product Portfolio

    Slide 11: Aversion Opioid Product Portfolio

    11 Aversion® Opioid Product Portfolio • Focus on rapid development of Hydrocodone/APAP • Demonstrated application to multiple opioid formulations Product Area Technology Licensee Status Oxycodone HCL, USP CII Opioid Aversion Pfizer Marketed in the U.S. Hydrocodone/APAP Opioid Aversion * In Developme

  12. Slide 12: Abuse of Opioids is Prevalent

    Slide 12: Abuse of Opioids is Prevalent

    • 35 million people in the United States have used Rx opioids non - medically in their lifetime • Immediate Release (IR) opioids are more frequently abused than Extended Release (ER) opioids Abuse of Opioids is Prevalent Source: SAMHSA, Office of Applied Studies, 2009 National Survey on Drug Use and

  13. Slide 13: Physician Perception of Opioid Abuse

    Slide 13: Physician Perception of Opioid Abuse

    Physician Perception of Opioid Abuse Source: Company Research, 400 Primary Care, Surgeon, Pain Specialists & Emergency Room Physicians, December 2011 • Snorting and Injecting are the methods with the highest concern for serious adverse health consequences with immediate release opioids 13

  14. Slide 14: Aversion IR Product Markets

    Slide 14: Aversion IR Product Markets

    Aversion IR Product Markets Oxycodone/APAP Hydrocodone/APAP Oxycodone Only Source: IMS NPA, MAT Dec. 2011 • 188 million dispensed prescriptions in 2011 • $1.7 billion in sales (mostly generic prices) 14

  15. Slide 15: Aversion Oxycodone HCl Tablets CII

    Slide 15: Aversion Oxycodone HCl Tablets CII

    • FDA Approval : June 17, 2011 • Marketed By : Pfizer, Inc. • First Commercial Sale : February 2, 2012 • Brand Name: Oxecta ® • Direct Market Size : 14.8 million annual IR oxycodone Rx’s Aversion® Oxycodone HCl Tablets CII Source: IMS NPA, MAT Dec. 2011 Oxecta is a registered trademark of Pfizer Inc

  16. Slide 16: Aversion Hydrocodone/APAP

    Slide 16: Aversion Hydrocodone/APAP

    Aversion® Hydrocodone/APAP • Development Status (completed by Pfizer) • Bioequivalence demonstrated to the Reference Listed Drug • Pre - IND meeting held with the FDA • Assessment of formulation stability ongoing • Expected Acura Clinical Development Program • 505(b)(2) New Drug Application - Priori

  17. Slide 17: Intellectual Property Position

    Slide 17: Intellectual Property Position

    • Aversion® Technology patents expire in 2025 • 3 U.S. patents issued covering compositions of opioids and certain other abused drugs with functional inactive ingredients • 1 U.S. Patent issued covering an extended release opioid dosage form • Impede™ Technology patents pending • Additional U.S. and

  18. Slide 18: Financial Information

    Slide 18: Financial Information

    Financial Information Parca i

  19. Slide 19: Selected Financial Information

    Slide 19: Selected Financial Information

    19 Selected Financial Information $ Millions Cash and Cash Equivalents (6/30/12) $31.2 Debt (6/30/12) None Shares Outstanding at 6/30/12 Millions Total Common Shares Outstanding 45.864 Shares Held by GCE Holdings (~72%) 33.064 • Sufficient cash to execute current business plan through at least the n

  20. Slide 20: Acura Pharmaceuticals, Inc.

    Slide 20: Acura Pharmaceuticals, Inc.

    Acura Pharmaceuticals, Inc. 616 N. North Court, Suite 120 Palatine, IL 60067 (847) 705 - 7709 NASDAQ: ACUR www.AcuraPharm.com Copyright © 2012 Acura Pharmaceuticals. All rights reserved.

Source: SEC EDGAR · 8-K filed Sep 4, 2012

More decks from Acura Pharmaceuticals, Inc.

All 11 Acura Pharmaceuticals decks